Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04675294 · ClinicalTrials.gov registry record · Phase 2
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
A Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by ALX Oncology.
- Active
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
- 20
- Study locations
NCT04675294 is a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by ALX Oncology. The registered enrollment target is 189 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT04675294, a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by ALX Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG evorpacept
Study Locations (20)
California
- Hoag Hospital - Irvine
- University of California San Diego - La Jolla
Illinois
- Rush University Medical Center - Chicago
- Blessing Cancer Center - Quincy
Other
- Ashford Cancer Centre Research - Windsor Gardens
- Cliniques Universitaires Saint-Luc - Brussels
Florida
- H. Lee Moffitt Cancer Center - Tampa
Georgia
- Northwest Georgia Oncology Centers - Marietta
Maryland
- University of Maryland Medical System - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
New Jersey
- Rutgers Cancer Institute of New Jersey - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2021-04-02 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04675294
The ClinicalTrials.gov registry entry for NCT04675294 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (27% lower). The listed sponsor is ALX Oncology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT04675294 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Illinois, Other.
Frequently Asked Questions
What is clinical trial NCT04675294 about?
NCT04675294 is a clinical study titled "Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)". A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
What is the current status of trial NCT04675294?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2021-04-02. Estimated completion is 2026-06-30.
What conditions does trial NCT04675294 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04675294?
The interventions under investigation include: pembrolizumab (DRUG), evorpacept (DRUG).
Who is sponsoring clinical trial NCT04675294?
This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04675294 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Explore more on PlainTrial
Head and Neck Cancer
All registered trials for this condition
Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.